G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite this, lipidomics analysis revealed that G0S2 loss in K562 cells disrupts lipid metabolism and the authors proposed that these lipid profile changes, over the course of disease progression, reduce TKI sensitivity in CML [92].